{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-119791","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.459845+00:00","generated_at":"2026-05-30T06:53:19.252649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY","bullets":["Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).","Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.","Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).","Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.","Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-119791","json":"https://secwatch.observer/filing/0000950170-24-119791.json","markdown":"https://secwatch.observer/filing/0000950170-24-119791.md","text":"https://secwatch.observer/filing/0000950170-24-119791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/0000950170-24-119791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/bdsx-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:53:19.252649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}